系统性硬化症相关肌病的临床病理表型:大型多中心队列分析
该研究分析了52例因疑似肌病行肌肉活检的系统性硬化症患者的临床血清学和组织学表型,按组织学分为纤维化型和炎症型两组。纤维化型患者缺血性心脏病、传导异常或心律失常、抗拓扑异构酶I抗体阳性率更高,中位红细胞沉降率更快,治疗反应差且死亡率更高、累积生存率更低。
要点
- 纤维化型SSc肌病缺血性心脏病发生率38.5% vs 炎症型3.8%(P=0.011),死亡率42.9% vs 3.8%(P=0.004)。
- 纤维化型传导异常或心律失常61.5% vs 26.9%(P=0.036),抗拓扑异构酶I抗体阳性42.9% vs 11.5%(P=0.044)。
- 纤维化型中位红细胞沉降率53.5 mm/h vs 炎症型32.5 mm/h(P=0.013),累积生存率更低(P=0.035)。
核心结论
- 系统性硬化症相关肌病患者的评估需综合临床、血清学和组织病理学方面,因其具有结局预测能力。
- 基于临床病理特征至少可区分纤维化型和炎症型两种不同表型,两者间存在显著差异。
研究设计与样本
- 2002年11月至2020年9月,52例系统性硬化症患者因疑似肌病接受肌肉活检。
- 根据组织学发现是否仅有纤维化或纤维化伴显著炎症,将患者分为纤维化型和炎症型两个亚组。
- 比较两组间的临床数据、抗体谱、电生理检查、肌肉活检结果以及治疗、死亡率和生存数据。
主要发现
- 14例活检为纤维化型;26例为炎症型,可分类为皮肌炎(n=7)、坏死性肌病(n=4)和非特异性肌炎(n=15)。
- 另有12例肌肉活检报告为神经源性萎缩(n=2)或正常肌肉/轻微改变(n=10)。
- 与炎症型相比,纤维化型患者缺血性心脏病患病率更高(38.5% vs 3.8%,P=0.011)。
- 纤维化型患者传导异常或心律失常患病率更高(61.5% vs 26.9%,P=0.036),抗拓扑异构酶I抗体阳性率更高(42.9% vs 11.5%,P=0.044)。
- 纤维化型患者中位红细胞沉降率更快(53.5 mm/h vs 32.5 mm/h,P=0.013),治疗反应差,死亡率更高(42.9% vs 3.8%,P=0.004),累积生存率更低(P=0.035)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to analyse the clinico-serological and histological phenotypes of patients with SSc with associated myopathy. METHODS: From November 2002 to September 2020, 52 patients with SSc underwent a muscle biopsy for suspected myopathy. We established two subgroups according to the histological findings based on the presence of isolated fibrosis or fibrosis together with significant inflammation. These patterns were designated as fibrosing and inflammatory, respectively. Clinical data, antibody profile, electrophysiologic studies, muscle biopsy findings and data regarding treatment, mortality and survival were compared between the two groups. RESULTS: Fourteen biopsies had a fibrosing pattern, whereas 26 showed an inflammatory pattern that could be classified (according to the predominant pattern) into DM (n = 7), necrotizing myopathy (n = 4) and non-specific myositis (n = 15). Additionally, 12 muscle biopsies were reported as neurogenic atrophy (n = 2), or normal muscle or minimal changes (n = 10). Compared with the inflammatory group, SSc patients with the fibrosing pattern presented a higher prevalence of ischaemic heart disease (38.5% vs 3.8%, P = 0.011), conduction abnormalities or arrhythmias (61.5% vs 26.9%, P = 0.036), anti-topo I antibodies (42.9% vs 11.5%, P = 0.044), greater median ESR (53.5 mm/h vs 32.5 mm/h, P = 0.013), with poor response to treatment and a higher mortality (42.9% vs 3.8%, P = 0.004) and lower cumulative survival (P = 0.035). CONCLUSIONS: Patients with SSc-associated myopathy require a comprehensive approach that encompasses clinical, serological and histopathological aspects, given their outcome predictive capacity. At least two different phenotypes can be drawn, considering clinico-pathological features. Significant differences are delineated between both a fibrotic and an inflammatory phenotype.
引用
- Matas-García A, Guillén-Del-Castillo A, Kisluk B, et al. Clinico-pathological phenotypes of systemic sclerosis-associated myopathy: analysis of a large multicentre cohort. Rheumatology (Oxford). 2023. PMID: 35713496. doi:10.1093/rheumatology/keac361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。